Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cellzome extends Alzheimer’s disease collaboration with OMJP and J&J
August 2008
SHARING OPTIONS:

BOSTON—Cellzome Inc. has extended its Alzheimer's disease research collaboration with Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJP) and its affiliate, Johnson & Johnson Pharmaceutical Research & Development LLLC for two more years. Since 2005, the companies have worked to select and progress novel Gamma Secretase Modulators and novel targets from the Amyloid Precursor Protein (APP) pathway.

Under the new agreement, which has been extended to 2010, Cellzome will map the Tau pathway. OMJP has exclusive rights to the intellectual property on compounds chosen for clinical development and commercialization. In exchange, Cellzome receives a technology access fee and research support as well as milestones and royalties on sales. Further financial details were not disclosed. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.